

簡歷



姓名	郎慧珠
所屬單位	醫務管理研究所
職稱	教授
分機	7015
傳真	(02)2823-7298
Email	hclang@ym.edu.tw
研究領域及興趣	醫務管理研究法 醫療決策分析 醫療科技經濟評估 醫院作業管理

學歷

學校	科系	學位
美國約翰霍普金斯大學	醫療管理	博士
國立陽明大學	公共衛生	碩士
中國醫藥大學	公共衛生	學士

現職及經歷

單位	職位	期間
國立陽明大學醫學院醫務管理所	專任教授	2010-
國立陽明大學醫學院醫務管理所	專任副教授	2004-2010
國立陽明大學醫學院醫務管理所	專任助理教授	2000-2004

課程

醫療決策分析
醫療科技經濟評估
醫院作業管理

獎項與榮譽

陽明大學永久免接受評估教授 2020/2
陽明大學院級傑出教師 2019/12
陽明大學教師學術卓越獎勵 2019/8/1 - 2021/7/31
陽明大學教師學術卓越獎勵 2017/8/1 - 2019/7/31
陽明大學教師學術卓越獎勵 2013/8/1 - 2015/7/31
陽明大學教師學術卓越獎勵 2011/8/1 - 2013/7/31
國科會 99 年度補助大專院校獎勵特殊優秀人才 2010/10/1 - 2011/7/31
國家衛生研究院生涯發展獎助 2001 - 2005

著作目錄 (研究發表或出版著作)

1. Yang CP, Cheng HM, LuMC, Lang HC*. Association between continuity of care and survival in Taiwanese stroke patients: a 9-year cohort study. *PLoS One*. 2019 May 22; 14(5):ee0216495. doi: 10.1371/journal.pone. 0216495. eCollection 2019. MOST 105-2410-H-010 -012 -SS2
2. Cheng HM, Chiou LJ, Chen TC, Sung SH, Chen CH, Lang HC*. Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease-A five-year follow-up study. *Health Policy*. 2019 Feb;123(2):229-234. doi: 10.1016/j.healthpol.2018.11.010. Epub 2018 Nov 28. NSC 101-2410-H-010
3. Hsu CS, Lang HC, Huang KY, Chao YC, Chen CL. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. *HepatoInt*. 2018 Nov;12(6):531-543. doi: 10.1007/s12072-018-9905-7. Epub 2018 Nov 14. PMID: 30426396.
4. 蔣靜怡,郎慧珠.台灣診所之歇業與存活研究及其相關因素探討—以2000年至2010年新設西醫診所研究為例.台灣衛誌 2017年12月的第36卷第6期.
5. Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, Lu CL. Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study. *Hepatology*. 2017 Sep;66(3):896-907. doi: 10.1002/hep.29172. Epub 2017 May 8. NSC 101-2410-H-010
6. Sung SH, Chen TC, Cheng HM, Lee JC, Lang HC*, Chen CH*. Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. *Acta Cardiol Sin*. 2017 Jan;33(1):10-19.
7. Chiu YM, Chuang MT, Lang HC. Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study. *Rheumatol Int*. 2016 Nov;36(11):1507-1514. Epub 2016 Aug 17.
8. Lang HC, Chen HW, Chiou TJ, Chan AL. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. *J Med Econ*. 2016 Oct; 19(10); 923-7.
9. Hsu CS, Lang HC, Huang KY, Lin HH, and Chen CL. Association of Rheumatoid Arthritis and Hepatitis B infection: a Nationwide Nested Case-Control Study from 1999 to 2009 in Taiwan. *Medicine(Baltimore)*. 2016 May;95(18):e3551.
10. Lang HC, Lee HC, Lee SS, Lin HY, Chiu YM,. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: A population based trend study. *International Journal of Rheumatic Diseases*. *Int J Rheum Dis*.. 2016 Nov. 19(11): 1112-1118.doi: 10.1111/1756-185X.12813. Epub 2016 Feb 18.
11. Chen SF, Wang IJ, Lang HC*. Risk of major depression in patients with chronic renal failure on different treatment modalities: A matched-cohort and population-based study in Taiwan. *Hemodial Int*. 2016 Jan;20(1):98-105. doi: 10.1111/hdi.12334. Epub 2015 Jul 14.
12. Cheng JS, Tsai WC, Lin CL, Chen L, Lang HC, Hsieh HM, Shin SJ, Chen T, Huang CT, Hsu CC. Trend and factors associated with healthcare use and costs in type 2 diabetes mellitus: A decade experience of a universal health insurance program. *Med Care*. 2015 Feb;53(2):116-24.
13. Chiu YM, Lang HC*, Lin HY, Yang MT, Fang CH, Yan YW, Schabert VF, Tang B. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan. *Int J Rheum Dis*. 2014 Dec;17 Suppl 3:9-19.
14. Chiu YM, Lai MS, Lin HY, Lang HC, Lee LJ, Wang JD. Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. *Clin Exp Rheumatol*. 2014 Nov-Dec;32(6):898-903
15. Grøn KL, Ørnberg LM, Hetland ML, Aslam F, Khan N, Jacobs JWG, Henrohn D, Rasker H, Kauppi M, Lang HC, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis: results from 34 countries participating in the Quest-RA programme. *Clin Exp Rheumatol*. 2014 Nov-Dec;32(6):869-77 NSC 99-2410-H-010 -001
16. Chen HY, Chang HR, Lang HC*. Effects of Generic Drug substitution on Diabetes Therapy. *Patient Prefer Adherence*. 2014 Jan 29;8:127-33.
17. Shih CL, Chen CH, Sheu CF, Lang HC*, Hsieh CL. Validating and improving the reliability of the EORTC QLQ-C30 using a multidimensional Rasch model. *Value Health*. 2013 Jul-Aug;16(5):848-54.
18. Lang HC, Chang K, Ying YH*. Quality of Life, Treatment, and Patient Willingness to Pay for a Cure for Cervical Cancer in Taiwan. *Health Econ*. 2012 Oct;21(10):1217-33. (SCI).

19. Lang HC*, Wu SL. Lifetime Costs of the Top Five Cancers in Taiwan. *Eur J Health Econ.* 2012 Jun;13(3):347-53. (SCI).
20. Lang HC*. Willingness to Pay for Lung Cancer Treatment. *Value in Health* 2010; 13(6):743-9.). (SCI).
21. Lang HC*, Scheffler RM, Hu TW. The Discrepancy in Attention Deficit Hyperactivity Disorder (ADHD) Medications Diffusion: 1994-2003-A global pharmaceutical data analysis. *Health Policy* 2010;97:71-78. (SCI).
22. Lu CL, Lang HC, Luo JC, Liu CC, Lin HC, Chang FY, Lee SD. Increasing Trend of the Incidence of Esophageal Squamous Cell Carcinoma, but not Adenocarcinoma, in Taiwan. *Cancer Causes and Control.* 2010;21(2):269-74.(SCI).
23. Shiroywa T, Sung YK, Fukuda T, Lang HC, Bae, SC Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? *Health Econ.* 2010;19(4):422-37.(SCI).
24. Lang HC*, Chung L, Shun SC, Hsieh CL, Lan CF. Validation of EQ-5D in patients with cervical cancer in Taiwan. *Supportive Care in Cancer* 2010; 21(2): 269-74.(SCI). (Impact factor: 2.058;Rank: 25.00%)
25. Lang HC*, Li MS. Willingness to Pay to Sustain and Expand National Health Insurance Services in Taiwan. *BMC Health Service Research* 2008;8:261
26. Lang HC*, Wu JC, Yen SH, Lan CF, Wu SL. The lifetime Cost of Hepatocellular Carcinoma. *Applied Health Economics and Health Policy.* *Appl Health Econ Health Policy* 2008; 6 (1): 55-65.
27. Pu CY, Lan VM, Lan CF, Lang HC. The determinants of traditional Chinese medicine and acupuncture utilization for cancer patients with simultaneous conventional treatment. *Eur J Cancer Care.* 2008 ;17(4):340-9.
28. Lu CL, Lang HC, Chang FY, Chen CY, Luo JC, Lee SD. Social and medical impact, sleep quality and pharmaceutical costs of heartburn in Taiwan. *Aliment Pharmacol Ther* 2005;22: 739-47.
29. Lu CL, Chang FY, Lang HC, Chen CY, Luo JC, Lee SD. Gender Difference on the Symptoms, health seeking behavior, social impact and sleep quality in Irritable Bowel Syndrome: A Rome II-based survey in an apparent healthy adult Chinese population in Taiwan. *Aliment Pharmacol Ther* 2005;21: 1497-505.
30. Liu CM, Chien CW, Chou P, Liu JH, Chen VT, Wei J, Kuo YY, Lang HC. An Analysis of Job Satisfaction Among Physician Assistants in Taiwan. *Health Policy.* 2005; 73(1); 66-77.
31. Lu CL, Lang HC, Chang FY, Chen CY, Luo JC, Wang SS, Lee SD. Prevalence and Health/Social Impacts of Functional Dyspepsia in Taiwan: a Study Based on Rome Criteria Questionnaire Survey Assisted with Endoscopic Exclusion among a Physical Checkup Population. *Scand J Gastroenterology.* 2005; 40 (4): 402-411.
32. Lang HC*. Economic Grand Rounds: Patients' and Caregivers' Willingness to Pay for a Cure for Schizophrenia in Taiwan. *Psychiatr Serv.* 2005 Feb; 56(2): 149-51.
33. Lang HC*, Su TP. The Cost of Schizophrenia Treatment in Taiwan. *Psychiatric Services.* 2004; 55(8): 928-930.
34. Lang HC*, Lai MS, Chen GT. Expenditures and Prescription Policies for Diseases with High Utilization of the National Health Insurance. *Journal of Formosan Medical Association* 2004;103:180-5.
35. Lang HC*, Chi CH, Liu CM. Impact of Case Payment Reimbursement Method on the utilization and Costs of Laparoscopic Cholecystectomy. *Health Policy.* 2004;67:195-206.
36. Lu CL, Chen CY, Lang HC, Wang SS, Chang FY, Lee SD. Current Patterns of Irritable Bowel Syndrome Presenting in a Chinese Population of Taiwan: Based on the Rome II Questionnaire. *Aliment Pharmacol Ther.* 2003; 18: 1159-69.
37. Lee ML, Chen CJ, SU IJ, Chen KT, Yeh CC, King CC, Wu YC, Ho MS, Jiang DD, Lin WF, Lang HC, Lin T, Wang JT, Chen CH, SARS Prevention Task Force, Execute Yuan, Taiwan, R.O.C. WHO, Department of Communicable Disease Surveillance and Response, Taiwan SARS Investigative Team, CDC. Use of Quarantine to Prevent Transmission of Severe Acute Respiratory Syndrome—Taiwan, 2003. *MMWR* 2003; 680-683.
38. Lang HC*, Lee C. The Transition of Taiwan Provincial Hospital- A Survey of High Ranking Officials. *Chin J Public Health.* [Chinese] 2001;20(1); 15-26.
Lang HC*, Lan CF. Contingent Valuation Method- A Method to Elicit Willingness to Pay. *Public Health Quarterly.* [Chinese] 2001;27(4) 261~276.